肺癌合剂配合化疗治疗中晚期非小细胞肺癌的临床价值评价  

Clinical Value of Lung Cancer Mixture Combined With Chemotherapy in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：杨扬[1] 

机构地区：[1]长春中医药大学附属医院肿瘤血液科,吉林长春130000

出　　处：《中国卫生标准管理》2016年第23期138-139,共2页China Health Standard Management

摘　　要：目的探析肺癌合剂配合化疗治疗中晚期非小细胞肺癌的临床价值。方法选取晚期非小细胞肺癌患者54例,以随机法分为对照组与观察组,两组各有患者27例。对照组实施单纯化疗,观察组则在其基础上增加肺癌合剂治疗。对比两组疗效。结果在临床治疗有效率方面,对照组不及观察组,其差异具有统计学意义(P<0.05)。结论通过为中晚期非小细胞肺癌患者提供化疗治疗并配以肺癌合剂,临床治疗效果显著。Objective To investigate the clinical value of lung cancer mixture combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Select 54 cases of patients with advanced non-small cell lung cancer, were randonfly to control group and observation group, two patients in each group of 27 cases. Control group received chemotherapy, the observation group was added based on the mixture in the treatment of lung cancer. The efficacy of two groups were compared. Results The effective rate of clinical treatment, the control group is far less than the observation group, the difference was statistically significant （ P 〈 0.05 ） . Conclusion By providing chemotherapy for patients with advanced nonsmall cell lung cancer and combined with lung cancer mixture, it can be a significant clinical effect.

关 键 词：中晚期非小细胞肺癌 肺癌合剂 化疗 

分 类 号：R243[医药卫生—中医临床基础]